Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
The company reported net revenue of SEK 13.5 million for the full year 2025
The company allocated €56 million to research and development for next-generation line solutions
The reports will now be shared with relevant ministries and departments as a guidance framework
Subscribe To Our Newsletter & Stay Updated
